Navigation Links
ViroPharma to Present at Three October Healthcare Conferences
Date:10/1/2008

EXTON, Pa., Oct. 1 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the third annual JMP Securities Healthcare Focus Conference at 2:30 P.M. ET on Monday, October 6, 2008. The conference is being held at the Le Parker Meridien Hotel in New York.

ViroPharma also announced that Robert Doody, manager, corporate communications of ViroPharma, will present at the Maxim Group Growth Conference at 10:30 A.M. ET on Tuesday, October 7, 2008. The conference is being held at the Grand Hyatt in New York.

William Roberts, vice president, corporate communications of ViroPharma, will present at the second annual Natixis Bleichroeder Hidden Gems Conference at 8:30 A.M. ET on Monday, October 13, 2008. The conference is being held at the Waldorf=Astoria in New York.

ViroPharma's presentations will be webcast live for investors through http://www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in infectious diseases including cytomegalovirus (CMV) and non-toxigenic C. difficile (NTCD).


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma To Acquire Lev Pharmaceuticals
3. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
4. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
5. ViroPharma to Present at Two Upcoming Healthcare Conferences
6. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
7. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
8. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
9. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
10. ViroPharma to Present at the BIO CEO & Investor Conference
11. ViroPharma Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... LAKE CITY, UTAH. (PRWEB) , ... May 25, 2016 , ... ... efficiencies in healthcare information exchange, today announced that Charles W. Stellar has been named ... as WEDI’s interim CEO since January 2016. As an executive leader with more than ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding Company Ltd. ... the company’s orphan drug designation request covering BHV-4157 for the treatment of Spinocerebellar ... FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that is ...
(Date:5/24/2016)... --  MedyMatch Technology Ltd ., the data analytics healthcare company ... tools in the emergency room, announced today that it has ... Industries (IATI) BioMed Conference. The Conference is ... Life Sciences and Technology Week, and is being held May ... Tel Aviv, Israel . Gene Saragnese , ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... newly re-branded identity. The new Media Cybernetics corporate branding reflects a results-driven revitalization ... imaging and image analysis. The re-branding components include a crisp, refreshed logo and ...
Breaking Biology Technology:
(Date:3/11/2016)... -- --> --> ... Market by Technology (Pattern Recognition), by Component (Hardware, Software, ... (On-Premises and Cloud), by Industry Vertical and by Region ... global market is expected to grow from USD 12.49 ... at a CAGR of 19.1%. , ...
(Date:3/9/2016)... NEW YORK , March 9, 2016 ... current and future states of the RNA Sequencing (RNA ... in segments such as instruments, tools and reagents, data ... Analyze various segments of the RNA-Sequencing market such ... RNA-Sequencing services Identify the main factors affecting each segment ...
(Date:3/8/2016)... , March 8, 2016   Valencell ... technology, today announced it has secured $11M in ... GII Tech, a new venture fund being launched ... additional participation from existing investors TDF Ventures and ... funds to continue its triple-digit growth and accelerate ...
Breaking Biology News(10 mins):